It helps transport nitrogen, supports protein metabolism, and serves as a major fuel source for intestinal and immune cells
The honest clinical picture, however, is more measured than the marketing: both peptides are investigational , neither is FDA-approved, and human clinical evidence specific to the combination is limited
SCFAs can modulate neuroinflammation by regulating microglia homeostasis, inhibiting microglial activation and reducing neuroinflammatory responses (Silva et al., 2020)
Researchers found that GHK-Cu combines several properties directly relevant to age-related neurodegeneration: it regulates copper balance, increases antioxidant defenses, suppresses inflammatory signaling, promotes blood vessel growth, and stimulates nerve growth and neurotrophic factors
But prior to the program, GLP-1 (Glucagon-like peptide-1) medications were not approved for weight loss under the Medicare Part D plan without the presence of a comorbidity, such as Type 2 diabetes or sleep apnea